Results of Operations and Financial Condition. On February 12, 2026, Anebulo Pharmaceuticals, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the quarter ended December 31, 2025 and providing a business update. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of t…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On February 5, 2026, the Board of Directors (the “Board”) of Anebulo Pharmaceuticals, Inc., a Delaware corporation (“Anebulo” or the “Company”) approved the voluntary delisting of the Company’s common stock, par value $0.001 per share (“Common Stock”), from The Nasdaq Capital Market (“Nasdaq”) and the subsequent voluntary deregistration of the Common Stock with the Securities and Exchange Comm…

Results of Operations and Financial Condition. On November 13, 2025, Anebulo Pharmaceuticals, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the quarter ended September 30, 2025 and providing a business update. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of…

Results of Operations and Financial Condition. On September 29, 2025, Anebulo Pharmaceuticals, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the quarter and fiscal year ended June 30, 2025 and providing a business update. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Se…

Results of Operations and Financial Condition. On May 13, 2025, Anebulo Pharmaceuticals, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the quarter ended March 31, 2025 and providing a business update. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Secur…

Other Events. On April 11, 2025, the Company received a letter from the Staff of The Nasdaq Stock Market LLC (the “Nasdaq”) informing the Company, that based on its Current Report on Form 8-K filed with the Securities and Exchange Commission on April 7, 2025, disclosing that the Company’s stockholders had approved the removal of certain voting and transfer restrictions on shares of its common stock issued in its December 2024 private placement, Nasdaq had determined that the Company had regai…

The filing is about an amendment to the Incentive Plan, not a management change.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On February 20, 2025, the Company received a letter (the “Letter”) from The Nasdaq Stock Market (“Nasdaq”) stating that the Company failed to comply with Nasdaq Listing Rule 5635(b) (“Rule 5635(b)”), which requires stockholder approval prior to the issuance of securities when the issuance or potential issuance will result in a change of control of the Company. Prior to the Private Placement, t…

Entry Into a Material Definitive Agreement As previously disclosed, on December 22, 2024, Anebulo Pharmaceuticals, Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with 22NW Fund, LP (“22NW”), as well as other institutional accredited investors (the “Investors”), pursuant to which the Company issued to the Investors, in a private placement priced at-the-market (the “Private Placement”), an aggregate of 15,151,514 shares of C…

Results of Operations and Financial Condition. On February 14, 2025, Anebulo Pharmaceuticals, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the quarter ended December 31, 2024 and providing a business update. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of t…

Entry into a Material Definitive Agreement. On December 22, 2024, Anebulo Pharmaceuticals, Inc., a Delaware corporation (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with 22NW Fund, LP (“22NW”), a greater than 5% stockholder of the Company that is controlled by Aron English, a director of the Company, as well as other institutional accredited investors (the “Investors”), pursuant to which the Company agreed to issue and sell to the Investors, in a pri…

Based in part upon the representations of the Investors in the Purchase Agreement, the offering and sale of the securities will be made in reliance on the exemption afforded by Regulation D under the Securities Act, and corresponding provisions of state securities or “blue sky” laws. The securities will not be registered under the Securities Act or any state securities laws and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from the…

Change in Control of Registrant The information set forth in

Other Events. On December 23, 2024, the Company issued a press release announcing, among other things, the pricing of the Private Placement described above. The press release issued in connection with this announcement is attached as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference. The press release also announced that the Company had met with the Food and Drug Administration (the “FDA”) to discuss the development of intravenous selonabant and the initial plan for clinic…

Results of Operations and Financial Condition. On November 13, 2024, Anebulo Pharmaceuticals, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the quarter ended September 30, 2024 and providing a business update. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of…

and in the Corporate Presentation furnished as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended and shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the d…

Results of Operations and Financial Condition. On September 25, 2024, Anebulo Pharmaceuticals, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the quarter and fiscal year ended June 30, 2024 and providing a business update. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Se…

Results of Operations and Financial Condition. On May 15, 2024, Anebulo Pharmaceuticals, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the quarter ended March 31, 2024 and providing a business update. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Secur…

Results of Operations and Financial Condition. On February 13, 2024, Anebulo Pharmaceuticals, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the quarter ended December 31, 2023 and providing a business update. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of t…

Results of Operations and Financial Condition. On November 14, 2023, Anebulo Pharmaceuticals, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the quarter ended September 30, 2023 and providing a business update. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of…

Chief Executive Officer — Simon Allen: The CEO was terminated without cause and resigned from the Board.

Chief Financial Officer — Daniel George: The company appointed Daniel George as the part-time Chief Financial Officer, replacing Sandra A. Gardiner.

Results of Operations and Financial Condition. On September 20, 2023, Anebulo Pharmaceuticals, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the fiscal year ended June 30, 2023, and providing a business update. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of…

Termination of a Material Definitive Agreement. On August 29, 2023, Potrero Hill Advisors, LLC (“Potrero”) provided written notice to terminate that certain Master Services Agreement, dated as of March 2, 2023, by and between Anebulo Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Potrero (the “Master Services Agreement”), effective as of September 28, 2023 (the “Termination Date”). Under the terms of the Master Services Agreement, Potrero provides the Company with certain…

Acting Chief Financial Officer — Sandra A. Gardiner: Ms. Gardiner resigned as the Company’s Acting Chief Financial Officer, which could negatively impact the Company's financing and/or accounting function.